Antiphospholipid Antibodies in Mental Disorders

Abstract

Thrombotic events striking the central nervous system are clinical criteria for the antiphospholipid syndrome (APS). Besides these, neuropsychiatric non-APS criteria manifestations are increasingly described in patients with persistently positive antiphospholipid antibodies (aPL). Among these are psychiatric manifestations. Animal models mainly describe hyperactive behavior and anxiety associated with hippocampal abnormalities. Cases of associations with psychosis, mood disorders, bipolarity, anxiety, obsessive–compulsive behavior, and depression have been reported but are still rare. Systematic human clinical association studies are concordant with a risk of psychosis, depression (simple to major), and anxiety disorders, but these are limited and of inconstant methodological quality. Brain imaging in patients, also insufficiently investigated, shows early signs of hypoperfusion and of subtle diffuse white matter changes compatible with an alteration of the axonal structure and changes in the myelin sheath. Direct interactions of aPL with the brain cells, both on cell lines and on animal and human brain biopsies, targeting both glial cells, astrocytes, and neurons, can be demonstrated. These clusters of arguments make the association between psychiatric diseases and aPL increasingly plausible. However, a considerable amount of clinical research must still be performed in accordance with the highest standards of methodological quality. The therapeutic management of this association, in terms of both prevention and cure, currently remains unresolved.

Keywords

antiphospholipid antibodies - psychiatry - mental health - psychosis - mood disorders - depression - mania

Publication History

Article published online:
24 July 2024

• References

• 1 World Health Organization. Mental disorders. Accessed February 4, 2023 at: https://www.who.int/news-room/facts-sheet/deail/mental disorders.
• 2 Buckholtz JW, Meyer-Lindenberg A. Psychopathology and the human connectome: toward a transdiagnostic model of risk for mental illness. Neuron 2012; 74 (06) 990-1004
• 3 Drysdale AT, Grosenick L, Downar J. et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 2017; 23 (01) 28-38
• 4 Taquet M, Smith SM, Prohl AK. et al. A structural brain network of genetic vulnerability to psychiatric illness. Mol Psychiatry 2021; 26 (06) 2089-2100
• 5 Rahaman MA, Chen J, Fu Z. et al. Deep multimodal predictome for studying mental disorders. Hum Brain Mapp 2023; 44 (02) 509-522
• 6 Jørgensen H, Horváth-Puhó E, Laugesen K, Brækkan SK, Hansen JB, Sørensen HT. Venous thromboembolism and risk of depression: a population-based cohort study. J Thromb Haemost 2023; 21 (04) 953-962
• 7 Steiner D, Horváth-Puhó E, Jørgensen H, Laugesen K, Ay C, Sørensen HT. Risk of depression after venous thromboembolism in patients with hematological cancer: a population-based cohort study. Thromb Haemost 2023; (e-pub ahead of print).
• 8 Shlobin NA, Har-Even M, Itsekson-Hayosh Z, Harnof S, Pick CG. Role of thrombin in central nervous system injury and disease. Biomolecules 2021; 11 (04) 562
• 9 Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110 (12) 3909-3916
• 10 Müller-Calleja N, Hollerbach A, Royce J. et al. Lipid presentation by the protein C receptor links coagulation with autoimmunity. Science 2021; 371 (6534) eabc0956
• 11 Gelb S, Stock AD, Anzi S, Putterman C, Ben-Zvi A. Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. J Autoimmun 2018; 91: 34-44
• 12 Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997; 100 (03) 613-619
• 13 Ziporen L, Polak-Charcon S, Korczyn DA. et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol 2004; 11 (01) 67-75
• 14 Katzav A, Pick CG, Korczyn AD. et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001; 10 (07) 496-499
• 15 Shrot S, Katzav A, Korczyn AD. et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002; 11 (11) 736-743
• 16 Katzav A, Litvinjuk Y, Pick CG. et al. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res 2006; 169 (02) 289-293
• 17 Frauenknecht K, Katzav A, Grimm C, Chapman J, Sommer CJ. Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. Immunobiology 2013; 218 (04) 517-526
• 18 Frauenknecht K, Katzav A, Grimm C, Chapman J, Sommer CJ. Altered receptor binding densities in experimental antiphospholipid syndrome despite only moderately enhanced autoantibody levels and absence of behavioral features. Immunobiology 2014; 219 (05) 341-349
• 19 Katzav A, Menachem A, Maggio N, Pollak L, Pick CG, Chapman J. IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome. J Autoimmun 2014; 55: 86-93
• 20 Frauenknecht K, Katzav A, Weiss Lavi R. et al. Mice with experimental antiphospholipid syndrome display hippocampal dysfunction and a reduction of dendritic complexity in hippocampal CA1 neurones. Neuropathol Appl Neurobiol 2015; 41 (05) 657-671
• 21 Frauenknecht K, Leukel P, Weiss R. et al. Decreased hippocampal cell proliferation in mice with experimental antiphospholipid syndrome. Brain Struct Funct 2018; 223 (07) 3463-3471
• 22 Katzav A, Grigoriadis NC, Ebert T. et al. Coagulopathy triggered autoimmunity: experimental antiphospholipid syndrome in factor V Leiden mice. BMC Med 2013; 11: 92
• 23 Katzav A, Ben-Ziv T, Blank M, Pick CG, Shoenfeld Y, Chapman J. Antibody-specific behavioral effects: intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J Neuroimmunol 2014; 272 (1-2): 10-15
• 24 Weiss R, Bitton A, Ben Shimon M. et al. Annexin A2, autoimmunity, anxiety and depression. J Autoimmun 2016; 73: 92-99
• 25 Kurtz G, Müller N. The antiphospholipid syndrome and psychosis. Am J Psychiatry 1994; 151 (12) 1841-1842
• 26 Siu BW, Chow HM, Kwok SS, Li OL, Koo ML, Poon PW. Systemic lupus erythematosus as a cause of first-episode psychosis in the second trimester of pregnancy. East Asian Arch Psychiatry 2010; 20 (03) 145-150
• 27 Fernández Ga de Las Heras V, Gorriti MA, García-Vicuña R, Santos Ruiz JL. Psychosis leading to the diagnosis of unrecognized systemic lupus erythematosus: a case report. Rheumatol Int 2007; 27 (09) 883-885
• 28 Cardinal RN, Shah DN, Edwards CJ, Hughes GR, Fernández-Egea E. Psychosis and catatonia as a first presentation of antiphospholipid syndrome. Br J Psychiatry 2009; 195 (03) 272
• 29 Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford) 2008; 47 (10) 1498-1502
• 30 Lai JY, Wu PC, Chen HC, Lee MB. Early neuropsychiatric involvement in antiphospholipid syndrome. Gen Hosp Psychiatry 2012; 34 (05) 579.e1-579.e3
• 31 Karabekiroğlu A, Yılmaz A, Kocamanoğlu B. Acute psychotic symptoms: a manifestation of antiphospholipid syndrome or infarction of corpus callosum. Psychiatr Danub 2015; 27 (03) 280-282
• 32 Shabana M, Shalaby M, Alhumayed S, Alshehri A. Paediatric case report: primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone?. Int J Rheum Dis 2009; 12 (03) 170-173
• 33 Spyropoulou AC, Tsartsara EI, Angelopoulou A, Zervas IM. Psychiatric manifestations preceding fetal death in antiphospholipid syndrome. Gen Hosp Psychiatry 2010; 32 (02) 225-227
• 34 Raza H, Epstein SA, Pao M, Rosenstein DL. Mania: psychiatric manifestations of the antiphospholipid syndrome. Psychosomatics 2008; 49 (05) 438-441
• 35 Avari JN, Young RC. A patient with bipolar disorder and antiphospholipid syndrome. J Geriatr Psychiatry Neurol 2012; 25 (01) 26-28
• 36 Aneja J, Kuppili PP, Paul K, Panda S, Purohit A. Antiphospholipid syndrome presenting as treatment resistant bipolar disorder and thrombocytopenia in a young male. J Neuroimmunol 2020; 343: 577238
• 37 Roie EV, Labarque V, Renard M, Van Geet C, Gabriëls L. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med 2013; 75 (03) 326-330
• 38 Firer M, Sirota P, Schild K, Elizur A, Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol 1994; 14 (01) 73-78
• 39 Schwartz M, Rochas M, Weller B. et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998; 59 (01) 20-23
• 40 Schwartz M, Rochas M, Toubi E, Sharf B. The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment. J Psychiatry Neurosci 1999; 24 (04) 351-352
• 41 Hoirisch-Clapauch S, Nardi AE. Markers of low activity of tissue plasminogen activator/plasmin are prevalent in schizophrenia patients. Schizophr Res 2014; 159 (01) 118-123
• 42 Hallab A, Naveed S, Altibi A. et al. Association of psychosis with antiphospholipid antibody syndrome: a systematic review of clinical studies. Gen Hosp Psychiatry 2018; 50: 137-147
• 43 Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry 1990; 27 (08) 863-870
• 44 Delluc A, Rousseau A, Le Galudec M. et al. Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics. Br J Haematol 2014; 164 (02) 272-279
• 45 Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19 (01) 11-38
• 46 Maes M, Meltzer H, Jacobs J. et al. Autoimmunity in depression: increased antiphospholipid autoantibodies. Acta Psychiatr Scand 1993; 87 (03) 160-166
• 47 Gris JC, Cyprien F, Bouvier S. et al. Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. World J Biol Psychiatry 2019; 20 (01) 51-63
• 48 Bankole AA, Kazmi TR, Strazanac AR. Determination of the risk factors contributing to the development of neuropsychiatric lupus in a systemic lupus erythematosus cohort. Cureus 2021; 13 (12) e20129
• 49 Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol 1996; 167 (06) 1573-1578
• 50 Lin TS, Hsu PY, Chang CH. et al. Increased heterogeneity of brain perfusion is an early marker of central nervous system involvement in antiphospholipid antibody carriers. PLoS One 2017; 12 (08) e0182344
• 51 Sun SS, Liu FY, Tsai JJ, Yen RF, Kao CH, Huang WS. Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement-a preliminary report. Rheumatol Int 2003; 23 (06) 301-304
• 52 Kozora E, Uluğ AM, Erkan D. et al. Functional magnetic resonance imaging of working memory and executive dysfunction in systemic lupus erythematosus and antiphospholipid antibody-positive patients. Arthritis Care Res (Hoboken) 2016; 68 (11) 1655-1663
• 53 Pereira FR, Macri F, Jackowski MP. et al. Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms. Eur Radiol 2016; 26 (04) 959-968
• 54 Gris JC, Bouvier S, Molinari N. et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119 (11) 2624-2632
• 55 Caronti B, Calderaro C, Alessandri C. et al. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998; 11 (05) 425-429
• 56 Caronti B, Pittoni V, Palladini G, Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 1998; 156 (02) 211-219
• 57 Agostinis C, Biffi S, Garrovo C. et al. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood 2011; 118 (15) 4231-4238
• 58 Katzav A, Shoenfeld Y, Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2010; 38 (2-3): 196-200
• 59 Aronovich R, Gurwitz D, Kloog Y, Chapman J. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology 2005; 210 (10) 781-788
• 60 Rajput PS, Lyden PD, Chen B. et al. Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models. Neuroscience 2014; 281: 229-240
• 61 Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8 (02) 127-133
• 62 Read SL. Catatonia in thrombotic thrombocytopenic purpura: case report. J Clin Psychiatry 1983; 44 (09) 343-344
• 63 Imaz Roncero C, Soto Loza A. Un caso pseudopsiquiatrico por purpura trombotica thrombocitopénica. Actas Esp Psiquiatr 2000; 28 (04) 267-269
• 64 Han B, Page EE, Stewart LM. et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol 2015; 90 (08) 709-714
• 65 Carpenter LJ, Solomons L, Grabe HJ, Pavord S. The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol 2022; 59 (02) 115-119